The Mycoplasma Testing Market is expanding globally as pharmaceutical manufacturers, biotechnology companies, research institutes, and testing laboratories increase their focus on contamination detection. Market development is being supported by advances in molecular testing, expanding biologics production, and greater regulatory emphasis on manufacturing quality.

According to Market Research Future, the global Mycoplasma Testing Market was valued at USD 1.21 billion in 2025 and is projected to reach USD 3.52 billion by 2035, representing a CAGR of 10.20% over the 2026–2035 forecast period.

North America currently dominates the market, accounting for approximately 43.10% of global revenue in 2025. The region benefits from a strong concentration of pharmaceutical and biotechnology companies, advanced research infrastructure, and stringent quality requirements.

Europe is another important market, supported by its established biotechnology ecosystem and regulatory framework. Pharmaceutical manufacturers and contract development and manufacturing organizations in the region require reliable contamination testing to maintain quality across biological production workflows.

Asia-Pacific represents a particularly attractive growth opportunity. Market Research Future projects the region to grow at approximately 16.50% CAGR through 2035. Expanding biomanufacturing facilities in China, India, and Singapore are contributing to demand for laboratory testing capabilities and contamination-control solutions.

Competition within the industry includes companies providing testing instruments, reagents, molecular assays, laboratory services, and integrated quality-control solutions. Key companies identified by Market Research Future include Roche Diagnostics, Charles River Laboratories, Lonza Group, Thermo Fisher Scientific, Merck KGaA, and SGS SA.

Technology differentiation is expected to remain important as manufacturers seek faster and more automated testing. PCR platforms are gaining momentum because of their rapid detection capabilities, while culture-based testing continues to have an established role. Emerging digital PCR and isothermal amplification technologies may further expand the range of available testing solutions.

Future opportunities will also arise from outsourced testing, automated laboratory workflows, point-of-manufacturing testing, and data-driven contamination monitoring. As pharmaceutical and biotechnology production becomes more complex, reliable mycoplasma detection will remain an essential component of quality management and manufacturing assurance.